SELLAS Life Sciences Group, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended June 30, 2026, the following directors adopted trading plans under Rule 10b5-1 of the Exchange Act.
| Name | Title | Action | Date Adopted | Plan End Date | Aggregate Shares |
|---|---|---|---|---|---|
| John Varian | Director | Adoption of Rule 10b5-1 trading plan | 5/15/2026 | 5/15/2027 | 12,500 |
| David Scheinberg | Director | Adoption of Rule 10b5-1 trading plan | 5/18/2026 | 5/18/2027 | 20,000 |
| Robert Van Nostrand | Director | Adoption of Rule 10b5-1 trading plan | 6/11/2026 | 6/11/2027 | 12,500 |
Each of these Rule 10b5-1 trading plans were adopted for the sale of up to the indicated amount of shares in order to satisfy tax obligations that arise upon the vesting of previously granted restricted stock units. These trading plans were entered into during an open insider trading window.
No other director or officer adopted, modified, orterminated any contract, instruction, or written plan for the purchase or sale of securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K) during the three months ended June 30, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.